What is the appropriate naloxone dosing regimen for suspected opioid overdose in adults and children?

Naloxone Dosing for Suspected Opioid Overdose

For suspected opioid overdose in adults, administer naloxone 0.4–2 mg IV/IO/IM initially, titrating to reversal of respiratory depression and restoration of protective airway reflexes—not full consciousness—and repeat every 2–3 minutes as needed; for children, use 0.1 mg/kg IV/IO/IM with the same titration approach. 1

Adult Dosing

Initial Dose and Route Selection

• Intravenous/intraosseous administration is preferred because it provides the most rapid onset of action, which is critical in emergency situations 2
• Start with 0.4–2 mg IV/IO/IM as the initial dose 1, 2
• If IV access is unavailable, administer intramuscularly or subcutaneously 2
• For intranasal administration, use 2–4 mg and repeat every 2–3 minutes as needed 1

Titration Strategy

• Titrate naloxone to reversal of respiratory depression and restoration of protective airway reflexes, NOT to full consciousness 1, 3
• Repeat doses every 2–3 minutes if the desired degree of counteraction and improvement in respiratory function are not obtained 2
• If no response occurs after 10 mg total naloxone has been administered, question the diagnosis of opioid-induced toxicity 2

Continuous Infusion for Prolonged Effect

• For long-acting opioids or recurrent respiratory depression, initiate a continuous infusion at approximately two-thirds of the waking dose per hour 1, 3
• Prepare infusion by adding 2 mg naloxone to 500 mL normal saline or 5% dextrose (concentration 0.004 mg/mL) 2
• Use prepared mixtures within 24 hours; discard any remaining solution after this period 2

Pediatric Dosing

Standard Pediatric Dose

• Administer 0.1 mg/kg IV/IO/IM as the initial dose 1, 2
• If this dose does not produce the desired clinical improvement, give a subsequent dose of 0.1 mg/kg 2
• Maximum pediatric dose should not exceed adult dose 1

Neonatal Dosing

• For opioid-induced depression in neonates, use 0.01 mg/kg IV/IM/SC as the initial dose 2
• Repeat according to adult administration guidelines for postoperative opioid depression 2

Route-Specific Considerations

Intranasal Administration

• Higher-concentration intranasal naloxone (2 mg/mL) has efficacy similar to intramuscular naloxone with no difference in adverse events 4
• Lower-concentration intranasal formulations (2 mg/5 mL) are less effective than intramuscular naloxone but may be associated with decreased risk for agitation 4
• Nasal bioavailability is approximately 50% with mean time to maximum concentration of 15–30 minutes 5
• Intranasal uptake is likely slower than intramuscular, as reversal of respiration lags behind intramuscular naloxone in overdose victims 5

Intramuscular Administration

• Intramuscular doses may be necessary when IV route is unavailable 2
• Supplemental intramuscular doses produce a longer-lasting effect compared to IV administration 2
• However, intramuscular route has difficulty with titration and slower time to clinical effect compared to IV 6

Intravenous Administration

• IV route is recommended to facilitate precise titration of dose 6
• Provides the most rapid onset of action, which is critical in emergency situations 2

Special Populations and Scenarios

Mixed Opioid-Benzodiazepine Overdose

• When combined opioid and benzodiazepine poisoning is suspected, administer naloxone first (before other antidotes) for respiratory depression/respiratory arrest 1, 3
• Mixed drug overdoses are extremely common; do not assume isolated benzodiazepine poisoning without confirming absence of other substances 3

Postoperative Opioid Depression

• Use smaller incremental doses: 0.1–0.2 mg IV every 2–3 minutes to the desired degree of reversal (adequate ventilation and alertness without significant pain) 2
• Larger than necessary dosage may result in significant reversal of analgesia and increased blood pressure 2
• Too rapid reversal may induce nausea, vomiting, sweating, or circulatory stress 2

Synthetic Opioid (Fentanyl) Overdoses

• Fentanyl overdoses likely require higher doses of naloxone than heroin overdoses 5
• Initial parenteral doses of 0.4–0.8 mg are usually sufficient for heroin overdose, but synthetic opioids may necessitate escalation 5

Monitoring and Repeat Dosing

Duration of Action

• Naloxone is rapidly eliminated with a half-life of 60–120 minutes 5
• Duration of action of some opioids may exceed that of naloxone, requiring continued surveillance and repeated doses 2
• Duration of action of 1 mg IV is approximately 2 hours, possibly longer with intramuscular and intranasal administration 5
• Repeat doses may be required within 1–2 hour intervals depending on the amount, type (short- or long-acting), and time since last opioid administration 2

Continuous Monitoring

• Keep patients under continued surveillance because the duration of action of some opioids exceeds that of naloxone 2
• After flumazenil administration (if used for benzodiazepine component), continuous monitoring for at least 2 hours is recommended because resedation commonly occurs 1–2 hours later 3

Critical Pitfalls to Avoid

• Do not administer excessive doses that fully reverse analgesia, as this causes significant pain, hypertension, and withdrawal symptoms 2
• Do not assume a single dose will be sufficient; many opioids (especially long-acting formulations and fentanyl) outlast naloxone's effect 2, 5
• Do not delay repeat dosing; if respiratory depression persists or recurs, administer additional naloxone every 2–3 minutes 1, 2
• Do not mix naloxone with preparations containing bisulfite, metabisulfite, long-chain or high molecular weight anions, or any solution with alkaline pH 2
• Do not use prepared infusion mixtures beyond 24 hours 2
• Always have at least two doses available for layperson administration, as a single dose may be insufficient 5

Community Distribution

• All individuals with opioid use disorder should have access to naloxone to treat opioid overdose 7
• Community-wide distribution of naloxone to people who use opioids and their social networks has been associated with 25–46% lower community opioid overdose rates 7
• Naloxone is approved for over-the-counter sales, including by adolescents younger than 18 years 8